Intracellular signals, delivered in professional antigenpresenting cells following the engagement of major histocompatibility complex (MHC) class II molecules, activate a variety of cellular functions that also contribute to efficient antigen presentation. As far as human malignancies, the signaling ability of human leukocyte antigens (HLA) class II molecules is a rather wellcharacterized event in hematologic tumors; in contrast, very limited evidences are available in solid neoplasias of different histotypes that may constitutively express HLA class II antigens. Among solid malignancies, a significant proportion of human cutaneous melanomas have been shown to express HLA class II molecules, and cutaneous melanoma undoubtedly represents a 'model disease' to investigate tumor immunobiology, to unveil the molecular basis underlying the interactions between neoplastic cells and host's immune system, and ultimately to set up new bio-immunotherapeutic approaches. Upcoming preclinical evidences unveil a signaling potential of HLA-DR antigens expressed on melanoma cells, and suggest for the clinical implication of HLA class II molecules as novel therapeutic targets. Therefore, in this review, we will focus on the emerging role of HLA class II antigens as intracellular signal transducing elements in neoplastic cells of the melanocytic lineage, emphasizing their foreseeable role in targeted therapy of human melanoma and potentially of HLA class II antigens-positive tumors of different histology.
Introduction
In the last two decades, the genomic organization, the molecular structure, the mechanisms regulating the expression of major histocompatibility complex (MHC) class II molecules and their intracellular signaling ability have been extensively elucidated in professional antigen-presenting cells (APC) (Scholl and Geha, 1994; Reith and Mach, 2001) . In contrast, limited data are still available on the immunologic role and on the potential intracellular signaling ability of MHC class II molecules, and their human counterpart human leukocyte antigens (HLA), in nonprofessional APC.
As far as their immunologic role in neoplastic nonprofessional APC, HLA class II molecules play an important role in tumor progression due to their ability to present antigenic tumor peptides to T lymphocytes (Renkvist et al., 2001) . In this regard, experimental findings have shown that selected tumor-associated antigens (TAA) are effectively presented by HLA class II antigens to CD4 þ T cells (Renkvist et al., 2001; Tatsumi et al., 2003) . Furthermore, it has been demonstrated that solid tumor cells can themselves act as nonprofessional APC being directly able to stimulate the proliferation of autologous CD4 þ T cells (Heike et al., 1996) . However, it has also been suggested that tumor cells drive T cells in an anergy state that results in immunosuppression of tumor-reactive T-cell clones (Byrne and Halliday, 2003) .
Besides their immunologic properties, new findings support the notion that HLA-DR molecules may play a relevant role in targeted therapy of HLA-DR-positive hematopoietic malignancies. In fact, engineered human monoclonal antibodies (mAb) directed to HLA-DR molecules, with a direct and nonimmunologic tumoricidal activity against HLA-DR-positive hematopoietic tumors have been described (Nagy et al., 2002) . Thus, it is now crucial to further unveil the functional role of HLA-DR antigens expressed in solid malignancies, since they may represent additional candidates for targeted therapy of solid tumors.
Distribution of HLA-DR antigens in solid malignancies
The expression of HLA-DR antigens on nonprofessional APC has been observed under various pathologic conditions (for a review, see Altomonte et al., 1999) ; in this regard, it has long been established that solid malignancies of different histotype can express HLA-DR antigens (Cabrera et al., 1995) . Emerging experimental evidences indicate that HLA-DR antigens expressed on neoplastic cells can play an important role in tumor immunology, and that alterations in their levels of expression might affect tumor immune escape (Heike et al., 1996; Byrne and Halliday, 2003) . Based on this idea, different studies have focused on the prognostic value of HLA-DR antigens expression on solid malignancies; however, the results obtained so far are still contradictory.
HLA class II antigens have not or have exceptionally been detected on nevocellular nevi and on melanocytes (van Duinen et al., 1988) , suggesting a potential relationship between malignant transformation of melanocytic cells and appearance of HLA class II antigens on melanoma cells (Albino et al., 1986) . The analysis of freshly isolated melanoma cells showed HLA-DR antigens expression in 60 and 50% of primary and metastatic lesions, respectively (Taramelli et al., 1986) . In addition, the expression of HLA-DR antigens was found to be induced or upregulated on melanoma cells by TNF-a and by IFN-g (Maio et al., 1989) , suggesting that microenvironmental conditions at tumor sites might influence the phenotypic profile of melanoma lesions. The expression of HLA-DR antigens in melanoma lesions has also been extensively investigated to identify a potential correlation between the expression of HLA-DR antigens and the clinical outcome of patients (van Duinen et al., 1988; Si and Hersey, 1993; Ostmeier et al., 1999 Ostmeier et al., , 2001 Ricaniadis et al., 2001; Bernsen et al., 2003) ; nevertheless, a consensus correlating HLA-DR antigens expression in melanoma lesions and disease progression has not been reached yet.
A positive relationship between HLA-DR expression and prognosis was found in gastric (Hilton and West, 1990; Ma et al., 1994; Cabrera et al., 1995; Ishigami et al., 1998) and colorectal carcinoma (Rognum et al., 1983; Gutierrez et al., 1987; Norheim Andersen et al., 1993; Chang and Sohn, 1995; Lazaris et al., 1995; Morita et al., 1995; Kunihiro et al., 1998; Lovig et al., 2002) . Discordant findings regarding the levels of HLA-DR expression were reported in breast cancer (Natali et al., 1983; Bernard et al., 1984; Hurlimann and Saraga, 1985; Bartek et al., 1987; Walker, 1987, 1988; Koretz et al., 1989; Moller et al., 1989; Brunner et al., 1991; Concha et al., 1991; Lucin et al., 1994) . Furthermore, in breast cancer, the extent of HLA-DR expression appears to be related to tumor grade. In fact, two studies reported that none of the breast carcinomas that were negative or only focally positive for HLA-DR expression were well differentiated (Zuk and Walker, 1988; Brunner et al., 1991) ; in addition, high levels of HLA-DR antigens expression were detected on primary medullary breast carcinoma which is usually associated with a relatively favorable prognosis (Natali et al., 1983; Bartek et al., 1987; Yazawa et al., 1993; Feinmesser et al., 2000; Lazzaro et al., 2001) . In spite of these evidences, a number of studies failed to support a prognostic relevance of HLA-DR antigens in breast cancer (Perez et al., 1986; Wintzer et al., 1990; Lucin et al., 1994) .
Different patterns of HLA-DR expression were also reported for head and neck squamous cell carcinoma; in particular, different percentages of HLA-DR-positive samples, ranging from 8% (Esteban et al., 1989) to 70% (Houck et al., 1990; Mattijssen et al., 1991) , were found in different studies. Discordant findings were also described concerning the tumor grade that predominantly expresses HLA class II molecules: some authors reported that well-differentiated tumors express HLA-DR antigens (Esteban et al., 1989; Vora et al., 1997) , while others stated that poorly differentiated tumors are HLA-DR-positive (Houck et al., 1990; Mattijssen et al., 1991) .
HLA-DR antigens are more frequently expressed in osteosarcoma cells (11 out of 35 samples investigated) compared to nonmalignant bone tumors (3 out of 34 samples investigated). However, this overexpression is not a predictive marker for clinical response to neoadjuvant chemotherapy. Consistently, no difference in the clinical outcome of HLA-DR-positive and -negative osteosarcoma patients was demonstrated (Trieb et al., 1998) .
As far as primary lung cancer, HLA-DR antigens expression was detected in 16% of squamous cell carcinomas, 60% of adenocarcinomas and 59% of large cell carcinomas, while it was not detected in small cell lung cancer (SCLC) (Yazawa et al., 1999) .
Lastly, no conclusive data concerning the prognostic significance of HLA-DR antigens expression were obtained in esophageal (Sadanaga et al., 1994; Sumiyoshi et al., 1999) , renal (Saito et al., 1997; Brasanac et al., 1999) , urinary bladder (Ioachim et al., 2000) , and cervical carcinoma (Glew et al., 1992; Hilders et al., 1995) .
Regulation of MHC class II antigens expression
The expression of MHC class II molecules and their accessory molecules, including the invariant chain (Ii) and the HLA-DM, is primarily controlled by Class II transactivator protein (CIITA) (Chang and Flavell, 1995; Chin et al., 1995; Kern et al., 1995; Lu et al., 1997; Ting et al., 1997; Westerheide et al., 1997) . CIITA acts as the master regulator of MHC class II molecules expression, which not only controls the constitutive expression of MHC class II molecules on professional APC (Steimle et al., 1993 (Steimle et al., , 1994 , but also regulates the IFN-g-inducible MHC class II molecules expression on nonprofessional APC (Goodwin et al., 2001) .
Four different promoters that regulate CIITA transcription in a tissue-specific manner have been described (Muhlethaler-Mottet et al., 1997) . Promoter I (pI) drives CIITA expression in dendritic cells, while the function of the promoter II (pII) is unknown. Promoter III (pIII) is involved in the constitutive expression of MHC class II molecules in B cells and it can be activated by IFN-g. Promoter IV (pIV) primarly drives IFN-g-induced expression of CIITA in nonprofessional APC (Piskurich et al., 1998 (Piskurich et al., , 1999 SCLC and neuroblastoma (NB), the most aggressive adult and infant neuroendocrine cancers, respectively, are immunologically characterized by the absence or by a severe reduction in HLA class II molecules expression (Schwab et al., 2000) . Yazawa et al., (2002) suggested that in SCLC and in NB, the overexpression of human achaete-scute complex homologue (HASH)-1, L-myc, and N-myc, is responsible for the IFN-g-inducible CIITA transcription deficiency, and concluded that these complicated regulatory mechanisms may play an important role in the escape of SCLC and NB cells from antitumor immunity (Yazawa et al., 2002) .
At variance with other nonprofessional APC, in which HLA class II molecules expression ordinarily occurs only after exposure to IFN-g treatment, melanoma cells can commonly express HLA class II molecules constitutively; this is a rare or possibly unique phenotype for a nonprofessional APC. In this regard, it has been demonstrated that the constitutive expression of HLA class II molecules on melanoma cells is sustained by the constitutive expression of CIITA which is mediated by the activation of both pIII and IFN-ginducible pIV CIITA promoters (Goodwin et al., 2001) .
MHC class II antigens signaling in professional APC
MHC class II molecules are heterodimers composed of a and b polypeptides, both of which span the plasma membrane and have short cytoplasmic tails (Marsh et al., 2000) .
MHC class II ligands such as mAb and superantigens have been utilized to mimic MHC class II-peptide complex recognition by antigen-specific T-cell receptors (TCR). The engagement of MHC class II molecules leads to various cellular events in professional APC such as homotypic cell adhesion, upregulation or induction of cytokines release, expression of costimulatory molecules, regulation of cell proliferation, and, under certain conditions, to cell death (for a review, see Altomonte et al., 1999) . As for other ligand-receptor interactions, some of these cellular events depend on MHC class II ligand dimerization, generate cAMP and intracellular calcium flux, and are mediated by signaling pathways and secondary messengers including: protein kinase C (PKC), protein tyrosine kinase(s) (PTK), and phospholipase C (Scholl and Geha, 1994) .
Several studies have focused on the structural features, which allow MHC class II molecules to carry out different functions. In murine B cells, it has been shown that a six amino-acid (a.a.) region of the cytoplasmic domain of the b chain (in particular a a residues 225, 227, and 228) is required for antigen presentation, cAMP accumulation, PKCb translocation, and expression of costimulatory molecules (St-Pierre et al., 1989; Nabavi et al., 1992; Andre`et al., 1994; Harton et al., 1995; Laufer et al., 1997) . Instead, other MHC class II antigens-induced biochemical events, such as tyrosine phosphorylation, phosphoinositide hydrolysis, and calcium mobilization, were found to be unaffected by various combinations of truncated a or/and b chain of MHC class II molecules (Andreè t al., 1994) . Furthermore, it has been proposed that transmembrane and cytoplasmic regions are also involved in signaling via MHC class II molecules through different pathways. These two pathways must be at least partially cooperative since disruption of either regions leads to a loss of MHC class II antigeninduced B-cell differentiation (Wade et al., 1993; Harton et al., 1995) . Detailed analyses of the structural compartmentalization of MHC class II antigens signal-transducing ability also demonstrated that their engagement activates different signaling pathways through their association with other proteins (Andre`et al., 1994) . In fact, among benign and malignant B cells investigated, a proportion of MHC class II molecules was found to be associated, within large oligomeric protein complexes, with exchangeable components of the transmembrane 4 superfamily (TM4S) (Schick and Levy, 1993; Angelisova et al., 1994; Szollosi et al., 1996; Levy et al., 1998) , with VLA integrins (Rubinstein et al., 1996) and with the actin-based cytoskeleton at cytoplasmic level (Chia et al., 1994) . In addition, several evidences demonstrate that specific cellular activities evoked by the engagement of MHC class II antigens are regulated during distinct stages of immune cells maturation, thus suggesting for a maturation-specific functional activity of MHC class II antigens and of their associated cell membrane proteins (Truman et al., 1996a, b; Coral et al., 1997; Garban et al., 1998) .
MHC class II antigens signaling in tumor cells
The conflicting data available on the correlation between the histopathological detection of HLA class II molecules on tumor cells and prognosis of cancer patients raise several questions concerning their functional role in cancer biology/immunobiology: (1) Are they always functional? (2) Can they transduce intracellular signals as previously shown for professional APC? (3) Is their intracellular signaling ability restricted to distinct stages of neoplastic cell differentiation? (4) To what extent can they contribute to the biological behavior and/or to the clinical course of the disease?
Since melanoma cells can constitutively express HLA class II molecules, they have been frequently utilized among other malignancies as the prototype for nonprofessional APC. As previous demonstrated in professional APC (Altomonte et al., 1993) , triggering of HLA-DR molecules by the murine anti-HLA-DR mAb L243 mediated a significant inhibition of the proliferation of selected melanoma cells. This growth-inhibitory activity of mAb L243 associates with homotypic cell aggregation and with the delivery of intracellular signal(s) that results in the enhancement of tyrosine phosphorylation of multiple intracellular proteins, and in the reduction of DNA binding ability of nuclear transcription factors (Altomonte et al., 2003) .
In addition to the evidences above, we now report that among different proteins co-precipitated with HLA-DR molecules by the anti-HLA-DR mAb L243 from Mel 120 melanoma cells, a band with a molecular weight similar to b-1 integrin subunit can be detected (Figure 1 ). This finding indicates that HLA-DR antigens are partially coassociated with b-1 integrin in melanoma, suggesting the existence of a network of proteins that may play a role in signal transduction, cell adhesion, and motility in neoplastic cells of the melanocytic lineage (Figure 2 ). This idea is consistent with previous data obtained in lymphoid cells, showing the existence of a network of proteins that connects several cell surface molecules including HLA-DR antigens and integrins (Rubinstein et al., 1996) .
Altogether, these findings, although preliminary, indicate that HLA-DR molecules expressed on selected melanoma cells can play a functional role which is similar to that reported for professional APC.
Future perspectives
Preclinical studies have recently foreseen the potential therapeutic effects of engineered anti-HLA-DR mAb on lymphoma/leukemia cells (Dechant et al., 2002; Nagy et al., 2002; Stockmeyer et al., 2002) . As most presently utilized pharmacologic agents and radiation therapy, these antibodies against HLA-DR antigens are directly cytotoxic. The promise of this innovative therapeutic approach for cancer therapy is that cell death is a direct consequence of the antibody binding to its target on tumor cells, and that cell destruction following HLA-DR antigens engagement does not require additional immune mechanisms, which may be compromised in cancer patients.
Targeting of selected HLA-DR-positive melanoma cells by anti-HLA-DR mAb activates biochemical pathways that result in a significant inhibition of cell proliferation; these data strongly suggest that human melanoma, as well as other solid malignancies that lack effective therapeutic options in advanced I and lysed in 1% CHAPS to maintain noncovalent molecular associations; then, cell lysates were immunoprecipitated with the anti-HLA-DR mAb L243. After five washing with 0.5% CHAPS, the immunoprecipitate was separated on a nonreducing 10% SDS-PAGE polyacrylamide slab gel. Under these experimental conditions, among different proteins co-precipitated with HLA-DR molecules by mAb L243, a band with a molecular weight of 130 kDa, similar to b-1 integrin subunit, was detected (lane 1). Noteworthy, b-1 integrin subunit was not detectable on the melanoma cell pellet bound to PAS after eluition of mAb L243-immunoprecipitated components in 1% NP40 (lane 2); however, when the proteins eluted in 1% NP40 were re-precipitated with the anti-b-1 integrin mAb K20, the b-1 integrin band was still detectable (lane 3). When cell lysates were immunoprecipitated with the anti-b-1 integrin mAb K20, washed with 0.5% CHAPS, and separated on a nonreducing 10% SDS-PAGE polyacrylamide slab gel, b-1 integrin subunit was detected in association with low amounts of HLA-DR a and b chains (lane 4). Noteworthy, HLA-DR a and b chains were not detectable on the melanoma cell pellet bound to PAS after elution of mAb K20-immunoprecipitates in 1% NP40 (lane 5); however, when the proteins eluted in 1% NP40 were reprecipitated with the anti-HLA-DR mAb L243, HLA-DR a and b chains were still detectable (lane 6). Lanes 1-3 and 4-6 are from the same radiogram exposed for 4 and 12 h, respectively Abbreviations APC, antigen-presenting cells; CIITA, Class II transactivator protein; HLA, human leucocyte antigens; FAK, focal adhesion kinase; MHC, major histocompatibility complex; mAb, monoclonal antibody; NB, neuroblastoma; TAA, tumorassociated antigen; SCLC, small cell lung carcinoma
